Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $25M with net income of −$40M.
Q3 2026 key financials · XBRL
- Revenue
- $25M
- −25.9% QoQ
- Net income
- −$40M
- −551.1% QoQ
- Operating margin
- -3.5%
- Gross margin
- 27.0%
- EPS (diluted)
- −$1.09
- −505.6% QoQ
Source: XBRL data from the LIFECORE BIOMEDICAL, INC. DE (LFCR) Q3 2026 10-Q on SEC EDGAR. USD.
LIFECORE BIOMEDICAL, INC. DE Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $25.3M, down 19% YoY from $31.1M
- Gross margin 27.0% vs 25.0% YoY, gross profit $6.8M vs $7.8M
- CDMO largest segment at $17.8M, down 18%; HA manufacturing weakest decline, down 19% to $7.5M
- Cash $23.0M, operating cash flow $9.5M, revolving facility undrawn with $15.0M available
- Outlook: liquidity sufficient for at least 12 months, Series A redemption obligation $51.1M due December 28, 2026
Risk Factors
- New merger risk: closing depends on HSR Act clearance, with the waiting period scheduled to expire November 9, 2026
- Most material update: Alcon relationship risk, Alcon represented 52% of nine-month revenue and must maintain specified agreements
- Regulatory risk: additional governmental approval conditions could delay or prevent closing, or impose costs and operating limitations
- Operational risk: merger uncertainty could disrupt CDMO customer relationships and key personnel retention
- Financial risk: termination could require a $9,957,716 fee and leave debt maturing May 22, 2029
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LIFECORE BIOMEDICAL, INC. DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.